Lunit Surpasses 200 U.S. Hospitals Adopting Its Solutions... One Year After Volpara Acquisition

On May 19, Lunit, a medical artificial intelligence (AI) company, announced that the number of medical institutions in the United States that have adopted its breast cancer diagnostic AI solutions, 'Lunit INSIGHT MMG' and 'Lunit INSIGHT DBT,' has surpassed 200.

This achievement comes just one year after the acquisition of Volpara Health (Volpara) in May last year. It demonstrates that Lunit has firmly established its presence in the United States, the world’s largest healthcare market. By leveraging Volpara’s robust sales network in the U.S., Lunit has rapidly gained a foothold in the local market. Currently, approximately 400 radiologists across the United States are utilizing Lunit’s AI solutions.

Lunit and Volpara together support the analysis of more than 1 million mammography cases annually in North America. In particular, they are expanding their influence in the North American market by securing major medical institutions as clients, including 'Rezolut,' which operates more than 40 imaging centers across the United States; 'SimonMed Imaging,' the largest private outpatient radiology network in the U.S.; and 'UC Davis Health,' a leading university hospital network in the western United States.

The key factor behind Lunit’s rapid growth in the U.S. market is its differentiated AI technology. 'Lunit INSIGHT MMG' analyzes 2D mammography images to accurately detect suspicious lesions, with its excellence already validated in global markets such as Korea, Europe, and Asia. Furthermore, in the U.S., where 3D mammography is well developed, the 'Lunit INSIGHT DBT' solution is being recognized for its technological capabilities and is expanding its market share.

Lunit and Volpara plan to pursue mid- to long-term growth by building a comprehensive cancer management platform that goes beyond simple diagnostic solutions. To this end, the two companies introduced a new concept called the 'AI Ecosystem' at the Radiological Society of North America (RSNA 2024) last December. This integrated approach supports the entire process of cancer diagnosis and treatment with AI, from lesion detection to workflow optimization and patient engagement. Alongside this, 'Lunit INSIGHT Risk' was introduced, which, in conjunction with Volpara’s flagship software 'Risk Pathways,' predicts the risk of developing breast cancer within the next 1 to 5 years.

Lunit plans to apply for FDA approval for Lunit INSIGHT Risk in the United States in the second half of this year, and then begin full-scale global sales starting in North America. Seo Bumseok, CEO of Lunit, stated, "Supplying our solutions to 200 medical institutions in the U.S. and supporting the analysis of more than 1 million mammography cases annually within just one year of acquiring Volpara is a highly meaningful achievement that no other domestic company has accomplished." He added, "By combining Lunit’s AI technology with Volpara’s breast cancer expertise, we will continue to drive innovation in breast cancer management by improving workflow for medical professionals and providing accurate early diagnosis for patients."